Immunohistochemical Analysis of Prostein in Needle Core Biopsies of Acinar and Intraductal Prostatic Adenocarcinoma in Western Kenya Population

Swaya, Tyrus Omondi; Opondo, Dedan; Atandi, David O.; Guyah, Benard; Magak, Ng’wena Gideon

doi:10.26502/jcsct.5079164

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our research indicates that 87% of the primary tumors have maintained or even raised transcript levels compared to autologous nonmalignant tissue samples. When compared to cancers that are not organ-confined, prostein expression is notably higher in prostate cancer [138][139][140][141][142] . Researchers have discovered a peptide derived from prostein and presented by HLA-A*0201, which activates tumor-reactive cytotoxic T lymphocytes (CTLs) when CD8+ T cells are stimulated In vitro with dendritic cells filled with the peptide, and also found immunogenic T-cell epitopes, such as HLA-Cw*0501 and HLA-B*5101 [111,140,143] .…”

Section: Prosteinmentioning

confidence: 99%

New approaches and prospects of immunotherapy and gene therapy for prostate cancer

Bibi,

Sarkar

2024

J Transl Genet Genom

View full text Add to dashboard Cite

Prostate cancer stands as the most prevalent cancer globally, constituting 21% of all cancer diagnoses in male patients. Urgent optimization of prostate cancer care is essential, given that this disease claims 345,000 lives every year. These innovative approaches hold substantial promise for both researchers and patients, representing a beacon of hope in the inhibitory act against prostate cancer. Prostate cancer's gradual advancement deems it suitable for immune therapy, but trials in metastatic cases show limited effectiveness, likely due to compromised immunity. Hindered by defective cellular responses, an immune-suppressive microenvironment, emerging evidence and breakthroughs, such as CAR-T therapy, inspire cautious optimism for advanced prostate cancer immunotherapy. Tumors utilize tactics to escape immune recognition, promoting the proliferation of MDSCs, Treg cells, and TAMs. Immunotherapy targets prostate cancer by mostly expressed target proteins and overexpressed target proteins. Immune cells play a role in tumor development and metastasis in advanced prostate cancer. Modulating the tumor microenvironment presents therapeutic possibilities. Certain prostate cancer types exhibit potential responses to immune checkpoint inhibitors, yet obstacles remain, necessitating additional research for enhanced efficacy. Immunotherapy faces hurdles in prostate cancer—limited inflammation, scarce antigens, and a resistant microenvironment. Grasping resistance intricacies is pivotal. The identification of DNA's helical structure propelled global progress in disease treatment through gene therapy. Choosing gene therapy vectors is critical; viruses are potent but toxic, while nonviral options, though less toxic, encounter barriers affecting transfection. In the realm of prostate cancer treatment, immunotherapy and gene therapy are emerging as increasingly viable options.

show abstract